I-Mab Biopharma (IMAB) Provides Business Update, Report H1 22 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
August 30, 2022 6:00 AM EDTSeven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4BLemzoparlimab is on track for Phase 3 study for 1L MDSAmendment to the global partnership with AbbVie for certain new CD47 antibodies currently in development with up to US$1.295 billion in milestone paymentsSignificant progress made on the expanded uliledlimab phase 2 NSCLC clinical trial with more complete dataset to be expectedContinued focus on key value drivers of five clinical-stage assets with three potential BLAs within the next three yearsRepositioned commercialization strategy for felzartamab and... More
